![apoorvsinghasr's tweet photo. I tried avoiding analysing Shilpa Medicare for some personal love hate relationship with this company's name but now the time has come !
Why?
Read On!
οΏ½οΏ½οΏ½ββββββββββββββββββββββββββββ
π¬ SHILPA MEDICARE (NSE: SHILPAMED)
βββββββββββββββββββββββββββββ
The market has a photograph of Shilpa
Medicare from 2023.
In that photo: margins at 9%. ROCE
below 1%. Net Debt at βΉ904 Cr. A
company struggling to survive.
The market is still looking at that
photograph. The company in it no
longer exists.
In 9 months of FY26, Shilpa earned
βΉ146 Cr in adjusted profit.
Its entire FY25 profit was βΉ78 Cr.
The business already earned TWICE the
previous year's profit with one quarter
still remaining. And the six most
powerful engines haven't ignited yet.
By the end of this thread, you will
see exactly what the market's outdated
mental model is missing: six growth
engines currently priced at zero,
sitting inside a company already
compounding at record margins.
All data: Q3FY26 earnings call
(Feb 06, 2026), BSE/NSE filings,
Investor Presentations FY26,
Annual Report FY25, https://t.co/31hWWi2619.
All projections labeled as personal
estimates. Not investment advice.
β The market is pricing the old Shilpa.
You have the chance to price the new one.
βββββββββββββββββββββββββββββ
πΊοΈ SECTION 1: WHY THIS MOMENT MATTERS
βββββββββββββββββββββββββββββ
Indian pharma is entering its most
consequential decade since the 1990s
generics revolution.
Three structural forces are converging:
β Global oncology drug spending crosses
$500 billion by 2028
β The GLP-1 patent cliff opens a
$50B+ generics market in 2027-28
β The global ADC (Antibody Drug
Conjugate) market grows 25%+ per year
and needs manufacturing capacity
that barely exists outside the West
Every large-cap Indian pharma is
hunting these opportunities. Most are
starting from scratch.
Shilpa Medicare has been building
the infrastructure for all three
simultaneously for the past 4 years.
The consensus view on X and across
financial media right now?
"Expensive. Warning letter risk.
Inconsistent earnings. Avoid."
That consensus was formed looking at
FY23 data and never updated.
This is NOT a recovery story.
This is NOT a "wait for margins to
improve" thesis.
This IS a story about a pressure
cooker with six sealed valves. The
heat has been building for 4 years.
The first valve just opened. Five
remain sealed.
At βΉ370, you are paying only for the
steam you can already see escaping.
The sealed valves are free.
βββββββββββββββββββββββββββββ
βοΈ SECTION 2: WHAT SHILPA ACTUALLY IS
βββββββββββββββββββββββββββββ
Most people think Shilpa is an API
(Active Pharmaceutical Ingredient)
company that makes cancer drug
molecules and sells them to larger
pharma firms.
That was true in 2021.
Today, Shilpa is a three-layer
platform that is vertically integrating
up the pharma value chain in real time.
Layer 1 (Bottom): API Manufacturing
β 30+ oncology molecules
β Supplies 50+ countries globally
β Q3FY26 revenue: βΉ243 Cr (+11% YoY)
β Gross margin: ~50%
Layer 2 (Middle): Formulations
β Finished medicines (tablets,
patches, injections) sold to patients
β Built on top of own API advantage
β Q3FY26 revenue: βΉ177 Cr (+50% YoY)
β Gross margin: ~68-70%
β EU Formulations alone: βΉ73 Cr (+100% YoY)
Layer 3 (Top): Biologics + CDMO
β Next-gen protein drugs and cancer
medicines manufactured for global
pharma partners (CDMO) and own
pipeline (Biologics + ADC)
β Revenue: early stage, scaling
β Gross margin potential: 50-60%+
Each layer up the stack earns
more per rupee of revenue than the
layer below it.
Shilpa's moat is specific, not generic:
β REGULATORY MOAT: 500+ regulatory
filings across USFDA, EMA, PMDA,
Health Canada, TGA, ANVISA. This
took 15 years to build. No shortcut.
β VERTICAL INTEGRATION: API to
Formulation under one roof = cost
advantage every competitor paying
market rate for API cannot match.
β FIRST MOVER: India's first integrated
ADC facility. India's first NAFLD
therapy. India's first recombinant
albumin Phase I completion. These are
not marketing claims. They are
regulatory and clinical milestones
that require years of infrastructure.
βββββββββββββββββββββββββββββ
π SECTION 3: THE NUMBERS THAT
PROVE THE OLD NARRATIVE IS DEAD
βββββββββββββββββββββββββββββ
Here is the single number that
breaks the bear thesis completely:
9M FY26 Adj PAT: βΉ146 Cr.
FY25 FULL YEAR PAT: βΉ78 Cr.
Put that in human terms. If you ran
a tea stall that earned βΉ78 in 2025,
and by September 2026 you had already
earned βΉ146 with three months still
left, you would not call it a
recovering stall. You would call it
a completely different business.
That is exactly what has happened.
Q3 FY26 (Record Quarter):
β Revenue: βΉ411 Cr (+28.3% YoY)
Source: BSE filing, Feb 06, 2026
β EBITDA: βΉ115 Cr (+41% YoY)
β EBITDA Margin: 28% (all-time high β
)
β Adjusted PAT: βΉ55 Cr (+72% YoY)
β EU Formulations: βΉ73 Cr (+100% YoY)
9M FY26 Cumulatives:
β Revenue: βΉ1,110 Cr (+14% YoY)
β EBITDA: βΉ323 Cr (+26% YoY)
β Adj EBITDA Margin: 29%
β Adj PAT: βΉ146 Cr (+128% YoY)
Source: Q3FY26 concall, Feb 06, 2026
Balance Sheet Transformation:
β Net Debt FY24: βΉ904 Cr (the crisis)
β Net Debt FY25: βΉ558 Cr
β D/E Q3FY26: 0.26x (under control β
)
β Interest Coverage FY25: 2.6x
β Interest Coverage FY26E: ~4.6x
[Personal Estimate]
ROCE recovery (adjusted for
biologics CWIP not yet generating
revenue):
β FY23: 3.4%
β 9M FY26: 17.1%
Source: Q3FY26 concall, Keshav Bhutada
A 500 basis point ROCE improvement
in 3 years on an EXPANDING asset base.
Now you might ask: if the operating
performance is this strong, why is
the stock down from βΉ500 to βΉ370?
That is the right question. Here is
the honest answer.
Three concerns are suppressing
the re-rating:
π΄ Promoter holding fell 4.1% in one
quarter (44.23% to 40.13%, Dec 2025).
βΉ300 Cr worth of shares sold with no
official explanation. Real concern.
π΄ Cash Conversion Cycle: 350 days.
Inventory days: 309. The business
generates strong profit but traps
significant cash in working capital.
As revenue scales, so does this risk.
π΄ Jadcherla Warning Letter active
since October 2020. Form 483 with
8 observations issued November 2025.
US revenue from this unit: less than
1% of H1FY26. Overhang real.
Material impact: limited.
The market sees the three concerns.
It has stopped looking at what is
being built while those concerns exist.
Now let us look at what is being built.
βββββββββββββββββββββββββββββ
π SECTION 4: SIX VALVES. ALL SEALED.
ALL PRICED AT ZERO.
βββββββββββββββββββββββββββββ
This is the core of the thesis.
Say it plainly:
At βΉ370, the market is paying for
the API business and existing Nilotinib
EU run-rate. Nothing else.
Every engine below is currently
valued at approximately zero.
π΅ VALVE 1: ROTIGOTINE PATCH (EU + US)
Status: β
EMA APPROVED. LAUNCH IMMINENT.
The clearest, most imminent catalyst
in this entire thesis.
Rotigotine is a transdermal patch for
Parkinson's disease. A complex
formulation (not a simple tablet).
Fewer generic competitors. Higher
pricing power.
β EMA approval: December 2025 β
β EU commercial launch: Q1FY27
β USFDA ANDA filed: February 06, 2026 β
β EU market size: $222 million
β US market size: $112 million
Source: BSE filing Feb 06, 2026 +
https://t.co/NVpIoEpjeG Dec 2025
The same EU distribution partner
that built Nilotinib to βΉ290 Cr/year
is already in place for Rotigotine.
Revenue potential [Personal Estimate]:
β FY27E: βΉ50-80 Cr (EU year 1)
β FY28E: βΉ100-130 Cr (EU mature)
β FY29E: βΉ160-200 Cr (EU + US launch)
Current market price of this engine: βΉ0
π΅ VALVE 2: GLP-1 PEPTIDE PLATFORM
Status: π FACILITY BEING BUILT
The βΉ40 crore bet on a βΉ50,000 Cr
global window.
Every pharma company in the world
is hunting for reliable Semaglutide
and Liraglutide API supply before
the patent cliff hits in 2027-28.
Shilpa is building a 100+ kg peptide
facility. βΉ40 Cr of capex. H2FY27
completion. Liraglutide DMF already
filed (Q2FY26). Semaglutide validation
underway H2FY26.
Management's exact words, Feb 2026:
"Targeting the global GLP-1 patent
cliff in next 2-3 years. Facility will
produce 100kg+ of Semaglutide for
in-house and CDMO purposes."
Keshav Bhutada, Q3FY26 concall
βΉ40 Cr of capex chasing a single
CDMO contract worth βΉ200-500 Cr/year.
Revenue potential [Personal Estimate]:
β FY28E: βΉ80-150 Cr (CDMO batches)
β FY29E: βΉ200-400 Cr (scaled CDMO)
β FY30E: βΉ400-700 Cr (generics + CDMO)
Current market price of this engine: βΉ0
π΅ VALVE 3: ADC FACILITY + PIPELINE
Status: π Q4FY26 COMMISSIONING
India's first integrated ADC
manufacturing facility.
An ADC (Antibody Drug Conjugate) is
the most sophisticated oncology weapon
being developed globally right now.
An antibody acts as GPS. A chemotherapy
molecule is the payload. It kills only
cancer cells. It spares healthy tissue.
The ADC market is growing 25%+ CAGR.
Manufacturing capacity barely exists
outside 2-3 Western CDMOs.
Shilpa's facility covers payload
synthesis, linker chemistry, and
conjugation. End-to-end. No other
Indian company has this.
Key milestones:
β Facility: commissioning Q4FY26
β Own ADC (SBPL01): Phase I FY27
β Maptree: exclusive CDMO partner
Phase I human studies FY27
β Maptree Orphan Designation:
received for 2 indications β
Source: Q3FY26 concall transcript,
Alphastreet, Feb 08, 2026
What orphan designation means:
β 10 years US market exclusivity
β Priority regulatory review
β Premium pricing: 10-50x standard drugs
β Tax credits + fee waivers
One successful orphan ADC product
over its exclusivity period can be
worth more than Shilpa's current
entire market cap.
Revenue potential [Personal Estimate]:
β FY28E: βΉ30-80 Cr (CDMO trial)
β FY29E: βΉ100-200 Cr (commercial)
β FY30E: βΉ250-500 Cr (multiple programs)
Current market price of this engine: βΉ0
π΅ VALVE 4: NORΠ£ΠΠ‘Π (NODUCA)
Status: β
LAUNCHED. GROWING.
India's first and only therapy for
NAFLD (Non-Alcoholic Fatty Liver
Disease). Launched Q3FY26.
NAFLD affects 350 million Indians.
That is one in four people in this
country. Until Noduca, there was
literally no approved treatment for
any of them.
Management (Q3FY26 concall):
"Performance is exceeding expectations
and building a healthy order book."
First mover. First in class. 350 million
patients. Zero competition. Today.
β 3 large pharma distribution partners
+ Shilpa's own label in India
β RoW + US filings: FY27
β EU human studies: FY27
Revenue potential [Personal Estimate]:
β FY27E: βΉ50-80 Cr (India full year)
β FY28E: βΉ100-150 Cr (established)
β FY29E: βΉ150-250 Cr (global filings
convert to approvals)
EBITDA margin: 60%+ (own novel drug,
no API cost pressure, pricing power)
[Personal Estimate]
Current market price of this engine: βΉ0
π΅ VALVE 5: RECOMBINANT ALBUMIN
Status: π PHASE III. ORION DEAL SIGNED.
This is the most underappreciated
story in Indian pharma right now.
Human albumin is an ICU essential:
burns, liver disease, major surgery.
Current global supply: 100% plasma-
derived from donated blood. Limited.
Expensive. Supply-constrained.
Shilpa's sRbumin is made from
microbial cells. No donated blood.
Unlimited production. Safer.
What has already been accomplished:
β Phase I: completed August 2024 β
62 volunteers. Positive safety data.
First Indian company in history.
Source: PRNewswire, Aug 28, 2024
β Orion Corporation EU partnership:
signed May 2025 β
Exclusive EU distribution + marketing
+ sales. Major European pharma firm.
β Phase III India: ongoing (FY26)
β IMPD submission to EMA: Q4FY26 target
β India commercialization: FY28 guided
Source: Q3FY26 concall management
Global albumin market:
β 2026: $7.8 billion
β 2033: $13.1 billion
Source: CoherentMarketInsights 2026
Orion Corporation signing an exclusive
EU deal is the most powerful external
validation in this entire thesis. European
pharma companies do not sign distribution
exclusives with businesses that cannot
meet global quality standards. The
quality has been verified at the highest
level. The market has not noticed.
Revenue potential [Personal Estimate]:
β FY28E: βΉ30-80 Cr (India launch)
β FY29E: βΉ150-300 Cr (India + EU Orion)
β FY30E: βΉ400-700 Cr (full commercial)
Current market price of this engine: βΉ0
π΅ VALVE 6: AFLIBERCEPT BIOSIMILAR
Status: π PHASE III ONGOING
Aflibercept (brand: EYLEA) treats
wet AMD (age-related macular
degeneration). Standard of care.
Global market: approximately $5 billion.
Shilpa is in Phase III India for its
biosimilar version. EU Phase III
targeted for H1FY27. Out-licensed to
Alveolus Bio for global commercialization.
Eye biologics require double complexity:
ophthalmic formulation precision AND
biologic manufacturing capability.
Virtually no other Indian company
is at this stage.
Revenue potential [Personal Estimate]:
β FY28E: βΉ20-50 Cr (India launch)
β FY29E: βΉ80-150 Cr (India + global)
β FY30E: βΉ200-400 Cr (commercial scale)
Current market price of this engine: βΉ0
βββββββββββββββββββββββββββββ
Six engines. All priced at zero.
The market is pricing the steam
it can already see. The six sealed
valves are free. That is the
specific mispricing this post exists
to expose.
βββββββββββββββββββββββββββββ
π‘ SECTION 5: THE NEAR MISS
(WHERE SMART ANALYSTS GOT CLOSE)
βββββββββββββββββββββββββββββ
Most smart observers tracking Shilpa
in 2025 saw the Nilotinib EU scale-up
and concluded: "Formulations recovery
play. Buy on margin expansion."
They were almost exactly right.
They stopped one insight short.
The real insight is not that Nilotinib
EU is recovering Shilpa's margins.
The real insight is that Nilotinib EU
cash flow is FUNDING the construction
of six entirely different businesses
simultaneously. The recovery is the
foundation. The six engines are the
house being built on top of it.
The analysts who saw "margin recovery"
built a model that works if Nilotinib
holds and formulation mix improves.
That model gives a 20-30% upside.
The model that also prices the six
engines gives a 100-300% upside over
3-4 years. Same company. Same data.
Different second-order insight.
This is exactly the kind of gap that
creates asymmetric returns in markets.
The first conclusion is obvious. The
second requires connecting dots across
9 regulatory filings, 3 investor
presentations, and 5 concall transcripts.
βββββββββββββββββββββββββββββ
β οΈ SECTION 6: THE RISKS
(NON-NEGOTIABLE INTELLECTUAL HONESTY)
βββββββββββββββββββββββββββββ
A thesis without bear cases is not
a thesis. It is a promotional brochure.
Here are the three that matter most.
π΄ RISK 1: PROMOTER HOLDING DECLINE
Promoter holding: 44.23% (Sep 2025)
Promoter holding: 40.13% (Dec 2025)
Change: -4.1% in a single quarter.
Equivalent: ~βΉ300 Cr of shares sold.
Promoter pledge: 8.73% of holdings.
Official explanation: none provided.
This is the single most important
unresolved governance question in
this thesis.
Stock impact if selling continues:
20-30% correction on sentiment alone,
irrespective of business performance.
Lead indicator: BSE shareholding
pattern for March 2026 quarter,
due May 2026. If promoter falls
below 38% without explanation,
the investment thesis requires
immediate re-evaluation.
π΄ RISK 2: WORKING CAPITAL TRAP
FY25 Cash Conversion Cycle: 350 days.
Inventory Days: 309 (extremely high).
Receivable Days: 126 (rising trend).
Payable Days: 85 (fell from 156 FY24).
As revenue scales from βΉ1,500 Cr
toward βΉ2,500 Cr, each incremental
βΉ100 Cr of revenue could trap ~βΉ95 Cr
of additional working capital.
[Personal Estimate]
Strong PAT can coexist with a balance
sheet quietly deteriorating. The
P&L story looks great while cash
compounds in inventory and receivables.
Lead indicator: Inventory Days each
quarter on https://t.co/31hWWi2619. Below 280:
improving. Above 320: escalating risk.
π΄ RISK 3: BIOLOGICS CLINICAL FAILURE
βΉ822 Cr of Capital Work In Progress
on the FY25 balance sheet (March 2025).
This represents biologics facilities,
ADC infrastructure, and clinical assets.
Globally, clinical failure rates exceed
50% even in Phase III trials.
If Aflibercept or SBPL01 face adverse
clinical results, a βΉ150-300 Cr
write-off is possible. [Personal Estimate]
That would erase 2-3 years of PAT
in a single accounting year.
The biologics story is simultaneously
the highest upside and highest risk
element of this investment case.
Lead indicator: CTRI India for
Aflibercept Phase III interim results.
Any SEBI filing announcing clinical
program termination.
βββββββββββββββββββββββββββββ
π SECTION 7: THE SCENARIO MAP
[Personal Estimates Only. Not SEBI
Research. Not Investment Advice.]
βββββββββββββββββββββββββββββ
CMP: βΉ370 (NSE close, Apr 02, 2026)
FY26E (Mar 2027):
π Bull: EPS βΉ10.2 Γ P/E 45x = βΉ459 (+24%)
If: Q4FY26 PAT > βΉ55 Cr, ADC confirmed
π Base: EPS βΉ9.5 Γ P/E 40x = βΉ380 (+3%)
If: Steady execution, licensing βΉ150 Cr
π» Bear: EPS βΉ7.4 Γ P/E 30x = βΉ222 (-40%)
If: Licensing miss + API price pressure
FY27E (Mar 2028):
π Bull: EPS βΉ14.5 Γ P/E 52x = βΉ754 (+104%)
If: ADC CDMO deal + GLP-1 partnership
π Base: EPS βΉ13.5 Γ P/E 42x = βΉ567 (+53%)
If: 20%+ rev growth, Rotigotine launches,
API external ramp begins Q2FY27
π» Bear: EPS βΉ10.5 Γ P/E 28x = βΉ294 (-21%)
If: Nilotinib EU competition, delays
FY28E (Mar 2029):
π Bull: EPS βΉ19 Γ P/E 55x = βΉ1,045 (+182%)
If: ADC commercial + Albumin EU + GLP-1
π Base: EPS βΉ17.5 Γ P/E 45x = βΉ788 (+113%)
If: Biologics contribute, FCF positive
π» Bear: EPS βΉ13 Γ P/E 32x = βΉ416 (+12%)
If: Clinical delays + Nilotinib lost
FY29E (Mar 2030):
π Bull: EPS βΉ25 Γ P/E 58x = βΉ1,450 (+292%)
π Base: EPS βΉ22 Γ P/E 50x = βΉ1,100 (+197%)
π» Bear: EPS βΉ15 Γ P/E 35x = βΉ525 (+42%)
FY30E (Mar 2031):
π Bull: EPS βΉ31 Γ P/E 60x = βΉ1,860 (+403%)
π Base: EPS βΉ28 Γ P/E 52x = βΉ1,456 (+294%)
π» Bear: EPS βΉ18 Γ P/E 38x = βΉ684 (+85%)
Read the bear column carefully.
FY26 bear: -40%. FY27 bear: -21%.
FY28 bear: +12%. FY30 bear: +85%.
Time compresses your downside and
expands your upside simultaneously.
This is what a multi-year compounder
looks like before the market sees it.
EV/EBITDA cross-check [Personal Est]:
FY27E EBITDA βΉ535 Cr Γ 20x = βΉ10,700 Cr EV
Less Net Debt βΉ520 Cr = MCap βΉ10,180 Cr
TP = βΉ10,180 / 195.5 Cr shares = βΉ521
Consistent with P/E base. β
Peer context (Apr 2026):
β Divi's Labs P/E: ~60x (zero debt,
pristine USFDA record, 20%+ ROCE)
β Laurus Labs P/E: ~60x (CDMO-led
re-rating, ROCE 10-12%, D/E 0.62x)
β Shilpa at βΉ370 = P/E ~27x on FY27E
[Personal Estimate]
Shilpa deserves parity to Laurus when
CDMO contribution becomes visible in
reported numbers. That has not happened
yet. That is the gap.
βββββββββββββββββββββββββββββ
π SECTION 8: MANAGEMENT QUALITY
βββββββββββββββββββββββββββββ
Keshav Bhutada (ED and CEO) scored
4.5 / 5 on concall quality metrics
from Q3FY26 (Feb 06, 2026):
β Proactively disclosed licensing
income down 40%+ in 9MFY26. Did not
bury it. Named it. Explained it. β
β Gave specific numbers: βΉ150 Cr annual
licensing run-rate, βΉ40 Cr peptide
capex, Q1FY27 Rotigotine EU launch. β
β Explained the API diversion mechanism
clearly: internal API diversion to
captive formulations, external ramp
from Q2FY27. β
β Every prior quarter's guidance was
reiterated and confirmed. β
Capital allocation track record:
β Reduced Net Debt βΉ346 Cr in one year
(βΉ904 Cr FY24 to βΉ558 Cr FY25) β
β INM merger tax benefit captured via
NCLT approval Q1FY26. Smart financial
engineering that saved real tax rupees. β
β Biologics CWIP βΉ822 Cr (Mar 2025):
high but represents real future assets.
GLP-1 capex βΉ40 Cr is disciplined
given the market opportunity size. β
The one unresolved concern:
β Promoter: 40.13% (Dec 2025), down
4.1% in one quarter. Pledge: 8.73%.
No public explanation provided. β οΈ
Operational quality: high.
Governance question: one open item.
Watch May 2026 shareholding filing.
βββββββββββββββββββββββββββββ
π
SECTION 9: CATALYST CALENDAR
(Next 18 Months, High to Low Impact)
βββββββββββββββββββββββββββββ
π΄ [CRITICAL] May 2026:
BSE Q4FY26 results + concall.
β ADC Q4FY26 commissioning: confirmed
or delayed?
β Full year FY26 PAT vs βΉ185 Cr base
[Personal Estimate]
β Management FY27 revenue guidance
π΄ [CRITICAL] May 2026:
BSE shareholding pattern (Mar 2026).
β Promoter direction: the most
important governance data point
in the next 6 months
π‘ [HIGH] Q1FY27 (Apr-Jun 2026):
Rotigotine EU first commercial revenue.
β EU Formulations above βΉ90 Cr in
Q1FY27 results = Rotigotine launched
β The first sealed valve opening in
reported numbers
π‘ [HIGH] H1 FY27 (by Sep 2026):
GLP-1 CDMO partnership announcement.
β Any signed CDMO deal for Semaglutide
or Liraglutide = immediate re-rating
(market cannot ignore $50B+ TAM)
π‘ [MED] Q4FY26 (by Jun 2026):
Albumin IMPD submission to EMA.
β Confirms the Orion EU partnership
is executing on schedule
β European commercial pathway opening
βββββββββββββββββββββββββββββ
π SECTION 10: THE VERDICT
βββββββββββββββββββββββββββββ
You now know three things most
market participants have missed:
1. THE MISPRICING:
The market's mental model of Shilpa
is built on FY23 data. The company
earning 2x its previous year's
profit in just 9 months, at 28%
EBITDA margins, with 17% adjusted
ROCE, is not the company in that
mental model. The narrative has not
caught up to the numbers.
2. THE DATA THAT PROVES IT:
Nine months. βΉ146 Cr adjusted PAT.
A signed EU albumin deal with Orion.
An ADC facility commissioning this
quarter. A GLP-1 plant being built
for βΉ40 Cr chasing a $50B+ market.
India's first NAFLD drug already
exceeding sales expectations.
Six engines priced at zero.
3. WHAT IT MEANS FOR THE NEXT
12-36 MONTHS:
FY26 base case upside is modest (+3%).
This is not a FY26 trade.
FY27 base case is +53%, with the first
sealed valve (Rotigotine EU) opening
visibly in reported quarterly numbers.
FY28 base case is +113%, if biologics
begin contributing even partially.
The bear case in FY30 still gives
you +85% from today's price.
Time is the most powerful risk manager
in this thesis.
The pressure cooker has been building
heat for 4 years. The first valve
opened in December 2025. Five remain
sealed. All five are priced at zero.
I have spent considerable time across
pharma balance sheets looking for
exactly this: a business where verified
execution is funding the construction
of optionalities the market cannot yet
see on any income statement. Shilpa at
βΉ370 is one of the clearest examples
of this structure I have encountered
in Indian small-cap pharma. The
combination of compounding core
business + free biologics optionality
+ disciplined management communication
is genuinely rare. That is not hype.
That is a specific, falsifiable claim
supported by the data in this thread.
The market is pricing the steam it
can already see escaping. Five valves
remain sealed. Five opportunities
are currently free.
Here is the question worth debating
in the comments: At exactly what
quarterly revenue milestone from
Rotigotine EU, GLP-1, or ADC does
the market's re-rating from API-
multiple to CDMO-biologics-multiple
actually trigger? βΉ50 Cr/quarter?
βΉ100 Cr/quarter? What is the number
that breaks the old narrative
irreversibly?
If you are reading a 360Β° pharma
thesis at this level of granularity,
you already know something most
market participants will only
understand after the re-rating
has happened. That window is now.
βββββββββββββββββββββββββββββ
β οΈ NOT SEBI registered research.
β οΈ NOT investment advice.
β οΈ ALL projections = personal estimates.
β οΈ Do your own research. Always.
#ShilpaMedicare #SHILPAMED
Follow for deep-dive equity research π
βββββββββββββββββββββββββββββ](https://pbs.twimg.com/media/HE7HmcAaUAAYH5c.png)
Olivia
Online
TheMarketMomentum
@TMMFib618
Data-driven Trading/Investment approach,
Momentum Trading, Dow Theory, Psychology, 5+ years of Market Experience
NSE, BSE, ASX
Not a SEBI Registered
AUSTRALIA
Joined March 2026
314 Following
59 Followers
86 Posts
Β Pinned Tweet
AEROFLEX INDUSTRIES LTD
What if I told you I was handing you a multibagger on a platter?
What would you do?
The company has all the essential ingredients to be a multibagger in the coming years!
The current market size of liquid cooling is $3 Billion, and it is projected to grow at a CAGR of 33%, reaching $21 billion over the next 6-7 years!
In this falling market, the technical chart is showing super strength.
What will it do when the market turns bullish again?
(This is not financial advice. DYOR)
(Originally tweeted on 14th March, mistakenly deleted)
#AEROFLEXIND
#AEROFLEX
#AEROFLEXINDLTD
#NSE
#BSE
#MULTIBAGGER
#MULTIBAGGERSTOCKS
#BREKAOUTSTOCKS
#INDIANSTOCKMARKET
FII is full-on bearish mode!
NIFTY 50 & BANKNIFTY VIEW
USDINR is rising again, and so is the price of CRUDE OIL!
This is a double-edged sword that hurts the Indian economy!
I would be careful about taking any bullish view on Nifty and Bank Nifty until oil and USDINR show a favorable move again.
DYOR!
#nifty50
#banknifty
#usdinrrising
#crudeoilrising
#inflation
GROWW (Billionbrains Garage Ventures Ltd)
Groww has proven it is the best growth engine, and FA and TA are both in line for a massive blast!
DYOR!
#multibaggerstocks
#breakoutstocks
#nse #bse #groww #BillionbrainsGarageVenturesLtd
Jain Resource Recycling Ltd
The magic happens when TA and FA are combined with a huge tailwind in the sector!
DYOR!
#multibaggerstocks
#nse #bse
Aeroflex Industries Ltd
Fill your bags before Goldman Sachs comes as an investor in May,2026.
The journey to 10X has just begun!!
DYOR!
#multibaggerstocks
#nse
#bse #nifty
#aeroflex
#aeroflexind
#AEROFLEX
Strong Bearish position from FIIs.
NIFTY 50 INDEX
The two possible pullbacks in Nifty 50! We need more data to see what is coming!
Crude Oil is making a higher low with RSI reset to make a new high!
INR is weakening, and the old resistance is now support!
#nifty50
#nse #bseb
#healthypullback
#massivecorrection
#USDINR #weakINR
BANK NIFTY
As the US$ and crude oil strengthen and the INR weakens, Bank Nifty might show a substantial correction.
Or it might show a small correction and then start going up again!
FII has made strong bearish positions!
Protect your capital!
DYOR!
#banknifty
#nse #bse #crudeoil #INRweaker
#strongUSDollar
#FII #DII
#niftycorrection
Zydus Wellness Ltd
One of the best of the next decade!
Clear monopoly in the Sugar-free sector, and the growth in the coming decade is going to be unbelievable with rising Diabetes in India!
#nse #bse #alltimehigh
#breakoutstocks
#zyduswellness
Reliance Power Ltd
One of the best turnaround stories!!!!
Fundamentals are getting better, and technicals are supporting the move with massive volume!
The stock is down almost 92% and showing a strong reversal from here onwards!
It is going to be one of the best turnaround stories of all time!
#nse
#bse
#powersector
#reliancepower
#niftystocks
#turnaroundstories
#reversalbreakouts
Yes Bank Ltd
The recent Q4 2026 is out, and the company's asset quality has improved massively, with Gross NPA 1.30% and Net NPA is 0.20%
PEG ratio is 0.26, and you will not see this stock at this price again!
The stock is down 96% from its all-time high, and now it will pick up momentum with strong fundamentals to back the growth!!
#nse #bse #banknifty
#YESBANK #yesbankstock #bankingstocks
#turnaroundstory #stockreversalbreakout
#turnaroundgrowthstocks
Ather Energy Ltd
Ather is ready for another bull run, with fuel prices rising!
The chart has shown perfect retracement and is ready for another bull run!
#nse
#bsebresult #breakoutstocks
#AtherEnergyLtd
#AtherEnergy
#growthstocks
AEROFLEX INDUSTRIES
Only those companies will go who are confident in their work to show it to the world!
More international orders on the way!
Bullish for Aeroflex Industries!
Way to go to Rs 1000 per share in 6 months' time!
#nse #bsebresult #Aeroflex #Aeroflexind
#breakout #alltimehigh #Strongmomentumstocks
AWL Agri Business Ltd
AWL is showing early signs of a reversal, with strong QonQ and YoY growth in double digits!
It can be a solid turnaround multibagger story!
The stock is almost 80% down from the all-time high, and it has made tremendous progress in the meantime, and now it is ready to deliver some solid growth numbers in the coming results!
#ReversalBreakout
#nse #bse
#AWL
#AWLAgriBusinessLtd
#turnaroundstory
#fillyourbags
#nifty
Praj Industries Ltd
The tide has changed for good! Bullish from here onwards!
The Accumulation phase is finished now, and the fundamental news is backing the technicals!
#nse #bse #niftyindia #PRAJIND
#turnaroundstocks
#fillyourbags
#stockreversal
#breakoutstocks
Capri Global Capital Ltd
This stock is one of the best Fundamental analysis and technical analysis combinations at the current price, with strong future growth!
DYOR!
#CGCL
#multibagger
#nse #bse #nifty50 #banknifty
I tried avoiding analysing Shilpa Medicare for some personal love hate relationship with this company's name but now the time has come !
Why?
Read On!
οΏ½οΏ½οΏ½ββββββββββββββββββββββββββββ
π¬ SHILPA MEDICARE (NSE: SHILPAMED)
βββββββββββββββββββββββββββββ
The market has a photograph of Shilpa
Medicare from 2023.
In that photo: margins at 9%. ROCE
below 1%. Net Debt at βΉ904 Cr. A
company struggling to survive.
The market is still looking at that
photograph. The company in it no
longer exists.
In 9 months of FY26, Shilpa earned
βΉ146 Cr in adjusted profit.
Its entire FY25 profit was βΉ78 Cr.
The business already earned TWICE the
previous year's profit with one quarter
still remaining. And the six most
powerful engines haven't ignited yet.
By the end of this thread, you will
see exactly what the market's outdated
mental model is missing: six growth
engines currently priced at zero,
sitting inside a company already
compounding at record margins.
All data: Q3FY26 earnings call
(Feb 06, 2026), BSE/NSE filings,
Investor Presentations FY26,
Annual Report FY25, https://t.co/31hWWi2619.
All projections labeled as personal
estimates. Not investment advice.
β The market is pricing the old Shilpa.
You have the chance to price the new one.
βββββββββββββββββββββββββββββ
πΊοΈ SECTION 1: WHY THIS MOMENT MATTERS
βββββββββββββββββββββββββββββ
Indian pharma is entering its most
consequential decade since the 1990s
generics revolution.
Three structural forces are converging:
β Global oncology drug spending crosses
$500 billion by 2028
β The GLP-1 patent cliff opens a
$50B+ generics market in 2027-28
β The global ADC (Antibody Drug
Conjugate) market grows 25%+ per year
and needs manufacturing capacity
that barely exists outside the West
Every large-cap Indian pharma is
hunting these opportunities. Most are
starting from scratch.
Shilpa Medicare has been building
the infrastructure for all three
simultaneously for the past 4 years.
The consensus view on X and across
financial media right now?
"Expensive. Warning letter risk.
Inconsistent earnings. Avoid."
That consensus was formed looking at
FY23 data and never updated.
This is NOT a recovery story.
This is NOT a "wait for margins to
improve" thesis.
This IS a story about a pressure
cooker with six sealed valves. The
heat has been building for 4 years.
The first valve just opened. Five
remain sealed.
At βΉ370, you are paying only for the
steam you can already see escaping.
The sealed valves are free.
βββββββββββββββββββββββββββββ
βοΈ SECTION 2: WHAT SHILPA ACTUALLY IS
βββββββββββββββββββββββββββββ
Most people think Shilpa is an API
(Active Pharmaceutical Ingredient)
company that makes cancer drug
molecules and sells them to larger
pharma firms.
That was true in 2021.
Today, Shilpa is a three-layer
platform that is vertically integrating
up the pharma value chain in real time.
Layer 1 (Bottom): API Manufacturing
β 30+ oncology molecules
β Supplies 50+ countries globally
β Q3FY26 revenue: βΉ243 Cr (+11% YoY)
β Gross margin: ~50%
Layer 2 (Middle): Formulations
β Finished medicines (tablets,
patches, injections) sold to patients
β Built on top of own API advantage
β Q3FY26 revenue: βΉ177 Cr (+50% YoY)
β Gross margin: ~68-70%
β EU Formulations alone: βΉ73 Cr (+100% YoY)
Layer 3 (Top): Biologics + CDMO
β Next-gen protein drugs and cancer
medicines manufactured for global
pharma partners (CDMO) and own
pipeline (Biologics + ADC)
β Revenue: early stage, scaling
β Gross margin potential: 50-60%+
Each layer up the stack earns
more per rupee of revenue than the
layer below it.
Shilpa's moat is specific, not generic:
β REGULATORY MOAT: 500+ regulatory
filings across USFDA, EMA, PMDA,
Health Canada, TGA, ANVISA. This
took 15 years to build. No shortcut.
β VERTICAL INTEGRATION: API to
Formulation under one roof = cost
advantage every competitor paying
market rate for API cannot match.
β FIRST MOVER: India's first integrated
ADC facility. India's first NAFLD
therapy. India's first recombinant
albumin Phase I completion. These are
not marketing claims. They are
regulatory and clinical milestones
that require years of infrastructure.
βββββββββββββββββββββββββββββ
π SECTION 3: THE NUMBERS THAT
PROVE THE OLD NARRATIVE IS DEAD
βββββββββββββββββββββββββββββ
Here is the single number that
breaks the bear thesis completely:
9M FY26 Adj PAT: βΉ146 Cr.
FY25 FULL YEAR PAT: βΉ78 Cr.
Put that in human terms. If you ran
a tea stall that earned βΉ78 in 2025,
and by September 2026 you had already
earned βΉ146 with three months still
left, you would not call it a
recovering stall. You would call it
a completely different business.
That is exactly what has happened.
Q3 FY26 (Record Quarter):
β Revenue: βΉ411 Cr (+28.3% YoY)
Source: BSE filing, Feb 06, 2026
β EBITDA: βΉ115 Cr (+41% YoY)
β EBITDA Margin: 28% (all-time high β
)
β Adjusted PAT: βΉ55 Cr (+72% YoY)
β EU Formulations: βΉ73 Cr (+100% YoY)
9M FY26 Cumulatives:
β Revenue: βΉ1,110 Cr (+14% YoY)
β EBITDA: βΉ323 Cr (+26% YoY)
β Adj EBITDA Margin: 29%
β Adj PAT: βΉ146 Cr (+128% YoY)
Source: Q3FY26 concall, Feb 06, 2026
Balance Sheet Transformation:
β Net Debt FY24: βΉ904 Cr (the crisis)
β Net Debt FY25: βΉ558 Cr
β D/E Q3FY26: 0.26x (under control β
)
β Interest Coverage FY25: 2.6x
β Interest Coverage FY26E: ~4.6x
[Personal Estimate]
ROCE recovery (adjusted for
biologics CWIP not yet generating
revenue):
β FY23: 3.4%
β 9M FY26: 17.1%
Source: Q3FY26 concall, Keshav Bhutada
A 500 basis point ROCE improvement
in 3 years on an EXPANDING asset base.
Now you might ask: if the operating
performance is this strong, why is
the stock down from βΉ500 to βΉ370?
That is the right question. Here is
the honest answer.
Three concerns are suppressing
the re-rating:
π΄ Promoter holding fell 4.1% in one
quarter (44.23% to 40.13%, Dec 2025).
βΉ300 Cr worth of shares sold with no
official explanation. Real concern.
π΄ Cash Conversion Cycle: 350 days.
Inventory days: 309. The business
generates strong profit but traps
significant cash in working capital.
As revenue scales, so does this risk.
π΄ Jadcherla Warning Letter active
since October 2020. Form 483 with
8 observations issued November 2025.
US revenue from this unit: less than
1% of H1FY26. Overhang real.
Material impact: limited.
The market sees the three concerns.
It has stopped looking at what is
being built while those concerns exist.
Now let us look at what is being built.
βββββββββββββββββββββββββββββ
π SECTION 4: SIX VALVES. ALL SEALED.
ALL PRICED AT ZERO.
βββββββββββββββββββββββββββββ
This is the core of the thesis.
Say it plainly:
At βΉ370, the market is paying for
the API business and existing Nilotinib
EU run-rate. Nothing else.
Every engine below is currently
valued at approximately zero.
π΅ VALVE 1: ROTIGOTINE PATCH (EU + US)
Status: β
EMA APPROVED. LAUNCH IMMINENT.
The clearest, most imminent catalyst
in this entire thesis.
Rotigotine is a transdermal patch for
Parkinson's disease. A complex
formulation (not a simple tablet).
Fewer generic competitors. Higher
pricing power.
β EMA approval: December 2025 β
β EU commercial launch: Q1FY27
β USFDA ANDA filed: February 06, 2026 β
β EU market size: $222 million
β US market size: $112 million
Source: BSE filing Feb 06, 2026 +
https://t.co/NVpIoEpjeG Dec 2025
The same EU distribution partner
that built Nilotinib to βΉ290 Cr/year
is already in place for Rotigotine.
Revenue potential [Personal Estimate]:
β FY27E: βΉ50-80 Cr (EU year 1)
β FY28E: βΉ100-130 Cr (EU mature)
β FY29E: βΉ160-200 Cr (EU + US launch)
Current market price of this engine: βΉ0
π΅ VALVE 2: GLP-1 PEPTIDE PLATFORM
Status: π FACILITY BEING BUILT
The βΉ40 crore bet on a βΉ50,000 Cr
global window.
Every pharma company in the world
is hunting for reliable Semaglutide
and Liraglutide API supply before
the patent cliff hits in 2027-28.
Shilpa is building a 100+ kg peptide
facility. βΉ40 Cr of capex. H2FY27
completion. Liraglutide DMF already
filed (Q2FY26). Semaglutide validation
underway H2FY26.
Management's exact words, Feb 2026:
"Targeting the global GLP-1 patent
cliff in next 2-3 years. Facility will
produce 100kg+ of Semaglutide for
in-house and CDMO purposes."
Keshav Bhutada, Q3FY26 concall
βΉ40 Cr of capex chasing a single
CDMO contract worth βΉ200-500 Cr/year.
Revenue potential [Personal Estimate]:
β FY28E: βΉ80-150 Cr (CDMO batches)
β FY29E: βΉ200-400 Cr (scaled CDMO)
β FY30E: βΉ400-700 Cr (generics + CDMO)
Current market price of this engine: βΉ0
π΅ VALVE 3: ADC FACILITY + PIPELINE
Status: π Q4FY26 COMMISSIONING
India's first integrated ADC
manufacturing facility.
An ADC (Antibody Drug Conjugate) is
the most sophisticated oncology weapon
being developed globally right now.
An antibody acts as GPS. A chemotherapy
molecule is the payload. It kills only
cancer cells. It spares healthy tissue.
The ADC market is growing 25%+ CAGR.
Manufacturing capacity barely exists
outside 2-3 Western CDMOs.
Shilpa's facility covers payload
synthesis, linker chemistry, and
conjugation. End-to-end. No other
Indian company has this.
Key milestones:
β Facility: commissioning Q4FY26
β Own ADC (SBPL01): Phase I FY27
β Maptree: exclusive CDMO partner
Phase I human studies FY27
β Maptree Orphan Designation:
received for 2 indications β
Source: Q3FY26 concall transcript,
Alphastreet, Feb 08, 2026
What orphan designation means:
β 10 years US market exclusivity
β Priority regulatory review
β Premium pricing: 10-50x standard drugs
β Tax credits + fee waivers
One successful orphan ADC product
over its exclusivity period can be
worth more than Shilpa's current
entire market cap.
Revenue potential [Personal Estimate]:
β FY28E: βΉ30-80 Cr (CDMO trial)
β FY29E: βΉ100-200 Cr (commercial)
β FY30E: βΉ250-500 Cr (multiple programs)
Current market price of this engine: βΉ0
π΅ VALVE 4: NORΠ£ΠΠ‘Π (NODUCA)
Status: β
LAUNCHED. GROWING.
India's first and only therapy for
NAFLD (Non-Alcoholic Fatty Liver
Disease). Launched Q3FY26.
NAFLD affects 350 million Indians.
That is one in four people in this
country. Until Noduca, there was
literally no approved treatment for
any of them.
Management (Q3FY26 concall):
"Performance is exceeding expectations
and building a healthy order book."
First mover. First in class. 350 million
patients. Zero competition. Today.
β 3 large pharma distribution partners
+ Shilpa's own label in India
β RoW + US filings: FY27
β EU human studies: FY27
Revenue potential [Personal Estimate]:
β FY27E: βΉ50-80 Cr (India full year)
β FY28E: βΉ100-150 Cr (established)
β FY29E: βΉ150-250 Cr (global filings
convert to approvals)
EBITDA margin: 60%+ (own novel drug,
no API cost pressure, pricing power)
[Personal Estimate]
Current market price of this engine: βΉ0
π΅ VALVE 5: RECOMBINANT ALBUMIN
Status: π PHASE III. ORION DEAL SIGNED.
This is the most underappreciated
story in Indian pharma right now.
Human albumin is an ICU essential:
burns, liver disease, major surgery.
Current global supply: 100% plasma-
derived from donated blood. Limited.
Expensive. Supply-constrained.
Shilpa's sRbumin is made from
microbial cells. No donated blood.
Unlimited production. Safer.
What has already been accomplished:
β Phase I: completed August 2024 β
62 volunteers. Positive safety data.
First Indian company in history.
Source: PRNewswire, Aug 28, 2024
β Orion Corporation EU partnership:
signed May 2025 β
Exclusive EU distribution + marketing
+ sales. Major European pharma firm.
β Phase III India: ongoing (FY26)
β IMPD submission to EMA: Q4FY26 target
β India commercialization: FY28 guided
Source: Q3FY26 concall management
Global albumin market:
β 2026: $7.8 billion
β 2033: $13.1 billion
Source: CoherentMarketInsights 2026
Orion Corporation signing an exclusive
EU deal is the most powerful external
validation in this entire thesis. European
pharma companies do not sign distribution
exclusives with businesses that cannot
meet global quality standards. The
quality has been verified at the highest
level. The market has not noticed.
Revenue potential [Personal Estimate]:
β FY28E: βΉ30-80 Cr (India launch)
β FY29E: βΉ150-300 Cr (India + EU Orion)
β FY30E: βΉ400-700 Cr (full commercial)
Current market price of this engine: βΉ0
π΅ VALVE 6: AFLIBERCEPT BIOSIMILAR
Status: π PHASE III ONGOING
Aflibercept (brand: EYLEA) treats
wet AMD (age-related macular
degeneration). Standard of care.
Global market: approximately $5 billion.
Shilpa is in Phase III India for its
biosimilar version. EU Phase III
targeted for H1FY27. Out-licensed to
Alveolus Bio for global commercialization.
Eye biologics require double complexity:
ophthalmic formulation precision AND
biologic manufacturing capability.
Virtually no other Indian company
is at this stage.
Revenue potential [Personal Estimate]:
β FY28E: βΉ20-50 Cr (India launch)
β FY29E: βΉ80-150 Cr (India + global)
β FY30E: βΉ200-400 Cr (commercial scale)
Current market price of this engine: βΉ0
βββββββββββββββββββββββββββββ
Six engines. All priced at zero.
The market is pricing the steam
it can already see. The six sealed
valves are free. That is the
specific mispricing this post exists
to expose.
βββββββββββββββββββββββββββββ
π‘ SECTION 5: THE NEAR MISS
(WHERE SMART ANALYSTS GOT CLOSE)
βββββββββββββββββββββββββββββ
Most smart observers tracking Shilpa
in 2025 saw the Nilotinib EU scale-up
and concluded: "Formulations recovery
play. Buy on margin expansion."
They were almost exactly right.
They stopped one insight short.
The real insight is not that Nilotinib
EU is recovering Shilpa's margins.
The real insight is that Nilotinib EU
cash flow is FUNDING the construction
of six entirely different businesses
simultaneously. The recovery is the
foundation. The six engines are the
house being built on top of it.
The analysts who saw "margin recovery"
built a model that works if Nilotinib
holds and formulation mix improves.
That model gives a 20-30% upside.
The model that also prices the six
engines gives a 100-300% upside over
3-4 years. Same company. Same data.
Different second-order insight.
This is exactly the kind of gap that
creates asymmetric returns in markets.
The first conclusion is obvious. The
second requires connecting dots across
9 regulatory filings, 3 investor
presentations, and 5 concall transcripts.
βββββββββββββββββββββββββββββ
β οΈ SECTION 6: THE RISKS
(NON-NEGOTIABLE INTELLECTUAL HONESTY)
βββββββββββββββββββββββββββββ
A thesis without bear cases is not
a thesis. It is a promotional brochure.
Here are the three that matter most.
π΄ RISK 1: PROMOTER HOLDING DECLINE
Promoter holding: 44.23% (Sep 2025)
Promoter holding: 40.13% (Dec 2025)
Change: -4.1% in a single quarter.
Equivalent: ~βΉ300 Cr of shares sold.
Promoter pledge: 8.73% of holdings.
Official explanation: none provided.
This is the single most important
unresolved governance question in
this thesis.
Stock impact if selling continues:
20-30% correction on sentiment alone,
irrespective of business performance.
Lead indicator: BSE shareholding
pattern for March 2026 quarter,
due May 2026. If promoter falls
below 38% without explanation,
the investment thesis requires
immediate re-evaluation.
π΄ RISK 2: WORKING CAPITAL TRAP
FY25 Cash Conversion Cycle: 350 days.
Inventory Days: 309 (extremely high).
Receivable Days: 126 (rising trend).
Payable Days: 85 (fell from 156 FY24).
As revenue scales from βΉ1,500 Cr
toward βΉ2,500 Cr, each incremental
βΉ100 Cr of revenue could trap ~βΉ95 Cr
of additional working capital.
[Personal Estimate]
Strong PAT can coexist with a balance
sheet quietly deteriorating. The
P&L story looks great while cash
compounds in inventory and receivables.
Lead indicator: Inventory Days each
quarter on https://t.co/31hWWi2619. Below 280:
improving. Above 320: escalating risk.
π΄ RISK 3: BIOLOGICS CLINICAL FAILURE
βΉ822 Cr of Capital Work In Progress
on the FY25 balance sheet (March 2025).
This represents biologics facilities,
ADC infrastructure, and clinical assets.
Globally, clinical failure rates exceed
50% even in Phase III trials.
If Aflibercept or SBPL01 face adverse
clinical results, a βΉ150-300 Cr
write-off is possible. [Personal Estimate]
That would erase 2-3 years of PAT
in a single accounting year.
The biologics story is simultaneously
the highest upside and highest risk
element of this investment case.
Lead indicator: CTRI India for
Aflibercept Phase III interim results.
Any SEBI filing announcing clinical
program termination.
βββββββββββββββββββββββββββββ
π SECTION 7: THE SCENARIO MAP
[Personal Estimates Only. Not SEBI
Research. Not Investment Advice.]
βββββββββββββββββββββββββββββ
CMP: βΉ370 (NSE close, Apr 02, 2026)
FY26E (Mar 2027):
π Bull: EPS βΉ10.2 Γ P/E 45x = βΉ459 (+24%)
If: Q4FY26 PAT > βΉ55 Cr, ADC confirmed
π Base: EPS βΉ9.5 Γ P/E 40x = βΉ380 (+3%)
If: Steady execution, licensing βΉ150 Cr
π» Bear: EPS βΉ7.4 Γ P/E 30x = βΉ222 (-40%)
If: Licensing miss + API price pressure
FY27E (Mar 2028):
π Bull: EPS βΉ14.5 Γ P/E 52x = βΉ754 (+104%)
If: ADC CDMO deal + GLP-1 partnership
π Base: EPS βΉ13.5 Γ P/E 42x = βΉ567 (+53%)
If: 20%+ rev growth, Rotigotine launches,
API external ramp begins Q2FY27
π» Bear: EPS βΉ10.5 Γ P/E 28x = βΉ294 (-21%)
If: Nilotinib EU competition, delays
FY28E (Mar 2029):
π Bull: EPS βΉ19 Γ P/E 55x = βΉ1,045 (+182%)
If: ADC commercial + Albumin EU + GLP-1
π Base: EPS βΉ17.5 Γ P/E 45x = βΉ788 (+113%)
If: Biologics contribute, FCF positive
π» Bear: EPS βΉ13 Γ P/E 32x = βΉ416 (+12%)
If: Clinical delays + Nilotinib lost
FY29E (Mar 2030):
π Bull: EPS βΉ25 Γ P/E 58x = βΉ1,450 (+292%)
π Base: EPS βΉ22 Γ P/E 50x = βΉ1,100 (+197%)
π» Bear: EPS βΉ15 Γ P/E 35x = βΉ525 (+42%)
FY30E (Mar 2031):
π Bull: EPS βΉ31 Γ P/E 60x = βΉ1,860 (+403%)
π Base: EPS βΉ28 Γ P/E 52x = βΉ1,456 (+294%)
π» Bear: EPS βΉ18 Γ P/E 38x = βΉ684 (+85%)
Read the bear column carefully.
FY26 bear: -40%. FY27 bear: -21%.
FY28 bear: +12%. FY30 bear: +85%.
Time compresses your downside and
expands your upside simultaneously.
This is what a multi-year compounder
looks like before the market sees it.
EV/EBITDA cross-check [Personal Est]:
FY27E EBITDA βΉ535 Cr Γ 20x = βΉ10,700 Cr EV
Less Net Debt βΉ520 Cr = MCap βΉ10,180 Cr
TP = βΉ10,180 / 195.5 Cr shares = βΉ521
Consistent with P/E base. β
Peer context (Apr 2026):
β Divi's Labs P/E: ~60x (zero debt,
pristine USFDA record, 20%+ ROCE)
β Laurus Labs P/E: ~60x (CDMO-led
re-rating, ROCE 10-12%, D/E 0.62x)
β Shilpa at βΉ370 = P/E ~27x on FY27E
[Personal Estimate]
Shilpa deserves parity to Laurus when
CDMO contribution becomes visible in
reported numbers. That has not happened
yet. That is the gap.
βββββββββββββββββββββββββββββ
π SECTION 8: MANAGEMENT QUALITY
βββββββββββββββββββββββββββββ
Keshav Bhutada (ED and CEO) scored
4.5 / 5 on concall quality metrics
from Q3FY26 (Feb 06, 2026):
β Proactively disclosed licensing
income down 40%+ in 9MFY26. Did not
bury it. Named it. Explained it. β
β Gave specific numbers: βΉ150 Cr annual
licensing run-rate, βΉ40 Cr peptide
capex, Q1FY27 Rotigotine EU launch. β
β Explained the API diversion mechanism
clearly: internal API diversion to
captive formulations, external ramp
from Q2FY27. β
β Every prior quarter's guidance was
reiterated and confirmed. β
Capital allocation track record:
β Reduced Net Debt βΉ346 Cr in one year
(βΉ904 Cr FY24 to βΉ558 Cr FY25) β
β INM merger tax benefit captured via
NCLT approval Q1FY26. Smart financial
engineering that saved real tax rupees. β
β Biologics CWIP βΉ822 Cr (Mar 2025):
high but represents real future assets.
GLP-1 capex βΉ40 Cr is disciplined
given the market opportunity size. β
The one unresolved concern:
β Promoter: 40.13% (Dec 2025), down
4.1% in one quarter. Pledge: 8.73%.
No public explanation provided. β οΈ
Operational quality: high.
Governance question: one open item.
Watch May 2026 shareholding filing.
βββββββββββββββββββββββββββββ
π
SECTION 9: CATALYST CALENDAR
(Next 18 Months, High to Low Impact)
βββββββββββββββββββββββββββββ
π΄ [CRITICAL] May 2026:
BSE Q4FY26 results + concall.
β ADC Q4FY26 commissioning: confirmed
or delayed?
β Full year FY26 PAT vs βΉ185 Cr base
[Personal Estimate]
β Management FY27 revenue guidance
π΄ [CRITICAL] May 2026:
BSE shareholding pattern (Mar 2026).
β Promoter direction: the most
important governance data point
in the next 6 months
π‘ [HIGH] Q1FY27 (Apr-Jun 2026):
Rotigotine EU first commercial revenue.
β EU Formulations above βΉ90 Cr in
Q1FY27 results = Rotigotine launched
β The first sealed valve opening in
reported numbers
π‘ [HIGH] H1 FY27 (by Sep 2026):
GLP-1 CDMO partnership announcement.
β Any signed CDMO deal for Semaglutide
or Liraglutide = immediate re-rating
(market cannot ignore $50B+ TAM)
π‘ [MED] Q4FY26 (by Jun 2026):
Albumin IMPD submission to EMA.
β Confirms the Orion EU partnership
is executing on schedule
β European commercial pathway opening
βββββββββββββββββββββββββββββ
π SECTION 10: THE VERDICT
βββββββββββββββββββββββββββββ
You now know three things most
market participants have missed:
1. THE MISPRICING:
The market's mental model of Shilpa
is built on FY23 data. The company
earning 2x its previous year's
profit in just 9 months, at 28%
EBITDA margins, with 17% adjusted
ROCE, is not the company in that
mental model. The narrative has not
caught up to the numbers.
2. THE DATA THAT PROVES IT:
Nine months. βΉ146 Cr adjusted PAT.
A signed EU albumin deal with Orion.
An ADC facility commissioning this
quarter. A GLP-1 plant being built
for βΉ40 Cr chasing a $50B+ market.
India's first NAFLD drug already
exceeding sales expectations.
Six engines priced at zero.
3. WHAT IT MEANS FOR THE NEXT
12-36 MONTHS:
FY26 base case upside is modest (+3%).
This is not a FY26 trade.
FY27 base case is +53%, with the first
sealed valve (Rotigotine EU) opening
visibly in reported quarterly numbers.
FY28 base case is +113%, if biologics
begin contributing even partially.
The bear case in FY30 still gives
you +85% from today's price.
Time is the most powerful risk manager
in this thesis.
The pressure cooker has been building
heat for 4 years. The first valve
opened in December 2025. Five remain
sealed. All five are priced at zero.
I have spent considerable time across
pharma balance sheets looking for
exactly this: a business where verified
execution is funding the construction
of optionalities the market cannot yet
see on any income statement. Shilpa at
βΉ370 is one of the clearest examples
of this structure I have encountered
in Indian small-cap pharma. The
combination of compounding core
business + free biologics optionality
+ disciplined management communication
is genuinely rare. That is not hype.
That is a specific, falsifiable claim
supported by the data in this thread.
The market is pricing the steam it
can already see escaping. Five valves
remain sealed. Five opportunities
are currently free.
Here is the question worth debating
in the comments: At exactly what
quarterly revenue milestone from
Rotigotine EU, GLP-1, or ADC does
the market's re-rating from API-
multiple to CDMO-biologics-multiple
actually trigger? βΉ50 Cr/quarter?
βΉ100 Cr/quarter? What is the number
that breaks the old narrative
irreversibly?
If you are reading a 360Β° pharma
thesis at this level of granularity,
you already know something most
market participants will only
understand after the re-rating
has happened. That window is now.
βββββββββββββββββββββββββββββ
β οΈ NOT SEBI registered research.
β οΈ NOT investment advice.
β οΈ ALL projections = personal estimates.
β οΈ Do your own research. Always.
#ShilpaMedicare #SHILPAMED
Follow for deep-dive equity research π
βββββββββββββββββββββββββββββ
![apoorvsinghasr's tweet photo. I tried avoiding analysing Shilpa Medicare for some personal love hate relationship with this company's name but now the time has come !
Why?
Read On!
οΏ½οΏ½οΏ½ββββββββββββββββββββββββββββ
π¬ SHILPA MEDICARE (NSE: SHILPAMED)
βββββββββββββββββββββββββββββ
The market has a photograph of Shilpa
Medicare from 2023.
In that photo: margins at 9%. ROCE
below 1%. Net Debt at βΉ904 Cr. A
company struggling to survive.
The market is still looking at that
photograph. The company in it no
longer exists.
In 9 months of FY26, Shilpa earned
βΉ146 Cr in adjusted profit.
Its entire FY25 profit was βΉ78 Cr.
The business already earned TWICE the
previous year's profit with one quarter
still remaining. And the six most
powerful engines haven't ignited yet.
By the end of this thread, you will
see exactly what the market's outdated
mental model is missing: six growth
engines currently priced at zero,
sitting inside a company already
compounding at record margins.
All data: Q3FY26 earnings call
(Feb 06, 2026), BSE/NSE filings,
Investor Presentations FY26,
Annual Report FY25, https://t.co/31hWWi2619.
All projections labeled as personal
estimates. Not investment advice.
β The market is pricing the old Shilpa.
You have the chance to price the new one.
βββββββββββββββββββββββββββββ
πΊοΈ SECTION 1: WHY THIS MOMENT MATTERS
βββββββββββββββββββββββββββββ
Indian pharma is entering its most
consequential decade since the 1990s
generics revolution.
Three structural forces are converging:
β Global oncology drug spending crosses
$500 billion by 2028
β The GLP-1 patent cliff opens a
$50B+ generics market in 2027-28
β The global ADC (Antibody Drug
Conjugate) market grows 25%+ per year
and needs manufacturing capacity
that barely exists outside the West
Every large-cap Indian pharma is
hunting these opportunities. Most are
starting from scratch.
Shilpa Medicare has been building
the infrastructure for all three
simultaneously for the past 4 years.
The consensus view on X and across
financial media right now?
"Expensive. Warning letter risk.
Inconsistent earnings. Avoid."
That consensus was formed looking at
FY23 data and never updated.
This is NOT a recovery story.
This is NOT a "wait for margins to
improve" thesis.
This IS a story about a pressure
cooker with six sealed valves. The
heat has been building for 4 years.
The first valve just opened. Five
remain sealed.
At βΉ370, you are paying only for the
steam you can already see escaping.
The sealed valves are free.
βββββββββββββββββββββββββββββ
βοΈ SECTION 2: WHAT SHILPA ACTUALLY IS
βββββββββββββββββββββββββββββ
Most people think Shilpa is an API
(Active Pharmaceutical Ingredient)
company that makes cancer drug
molecules and sells them to larger
pharma firms.
That was true in 2021.
Today, Shilpa is a three-layer
platform that is vertically integrating
up the pharma value chain in real time.
Layer 1 (Bottom): API Manufacturing
β 30+ oncology molecules
β Supplies 50+ countries globally
β Q3FY26 revenue: βΉ243 Cr (+11% YoY)
β Gross margin: ~50%
Layer 2 (Middle): Formulations
β Finished medicines (tablets,
patches, injections) sold to patients
β Built on top of own API advantage
β Q3FY26 revenue: βΉ177 Cr (+50% YoY)
β Gross margin: ~68-70%
β EU Formulations alone: βΉ73 Cr (+100% YoY)
Layer 3 (Top): Biologics + CDMO
β Next-gen protein drugs and cancer
medicines manufactured for global
pharma partners (CDMO) and own
pipeline (Biologics + ADC)
β Revenue: early stage, scaling
β Gross margin potential: 50-60%+
Each layer up the stack earns
more per rupee of revenue than the
layer below it.
Shilpa's moat is specific, not generic:
β REGULATORY MOAT: 500+ regulatory
filings across USFDA, EMA, PMDA,
Health Canada, TGA, ANVISA. This
took 15 years to build. No shortcut.
β VERTICAL INTEGRATION: API to
Formulation under one roof = cost
advantage every competitor paying
market rate for API cannot match.
β FIRST MOVER: India's first integrated
ADC facility. India's first NAFLD
therapy. India's first recombinant
albumin Phase I completion. These are
not marketing claims. They are
regulatory and clinical milestones
that require years of infrastructure.
βββββββββββββββββββββββββββββ
π SECTION 3: THE NUMBERS THAT
PROVE THE OLD NARRATIVE IS DEAD
βββββββββββββββββββββββββββββ
Here is the single number that
breaks the bear thesis completely:
9M FY26 Adj PAT: βΉ146 Cr.
FY25 FULL YEAR PAT: βΉ78 Cr.
Put that in human terms. If you ran
a tea stall that earned βΉ78 in 2025,
and by September 2026 you had already
earned βΉ146 with three months still
left, you would not call it a
recovering stall. You would call it
a completely different business.
That is exactly what has happened.
Q3 FY26 (Record Quarter):
β Revenue: βΉ411 Cr (+28.3% YoY)
Source: BSE filing, Feb 06, 2026
β EBITDA: βΉ115 Cr (+41% YoY)
β EBITDA Margin: 28% (all-time high β
)
β Adjusted PAT: βΉ55 Cr (+72% YoY)
β EU Formulations: βΉ73 Cr (+100% YoY)
9M FY26 Cumulatives:
β Revenue: βΉ1,110 Cr (+14% YoY)
β EBITDA: βΉ323 Cr (+26% YoY)
β Adj EBITDA Margin: 29%
β Adj PAT: βΉ146 Cr (+128% YoY)
Source: Q3FY26 concall, Feb 06, 2026
Balance Sheet Transformation:
β Net Debt FY24: βΉ904 Cr (the crisis)
β Net Debt FY25: βΉ558 Cr
β D/E Q3FY26: 0.26x (under control β
)
β Interest Coverage FY25: 2.6x
β Interest Coverage FY26E: ~4.6x
[Personal Estimate]
ROCE recovery (adjusted for
biologics CWIP not yet generating
revenue):
β FY23: 3.4%
β 9M FY26: 17.1%
Source: Q3FY26 concall, Keshav Bhutada
A 500 basis point ROCE improvement
in 3 years on an EXPANDING asset base.
Now you might ask: if the operating
performance is this strong, why is
the stock down from βΉ500 to βΉ370?
That is the right question. Here is
the honest answer.
Three concerns are suppressing
the re-rating:
π΄ Promoter holding fell 4.1% in one
quarter (44.23% to 40.13%, Dec 2025).
βΉ300 Cr worth of shares sold with no
official explanation. Real concern.
π΄ Cash Conversion Cycle: 350 days.
Inventory days: 309. The business
generates strong profit but traps
significant cash in working capital.
As revenue scales, so does this risk.
π΄ Jadcherla Warning Letter active
since October 2020. Form 483 with
8 observations issued November 2025.
US revenue from this unit: less than
1% of H1FY26. Overhang real.
Material impact: limited.
The market sees the three concerns.
It has stopped looking at what is
being built while those concerns exist.
Now let us look at what is being built.
βββββββββββββββββββββββββββββ
π SECTION 4: SIX VALVES. ALL SEALED.
ALL PRICED AT ZERO.
βββββββββββββββββββββββββββββ
This is the core of the thesis.
Say it plainly:
At βΉ370, the market is paying for
the API business and existing Nilotinib
EU run-rate. Nothing else.
Every engine below is currently
valued at approximately zero.
π΅ VALVE 1: ROTIGOTINE PATCH (EU + US)
Status: β
EMA APPROVED. LAUNCH IMMINENT.
The clearest, most imminent catalyst
in this entire thesis.
Rotigotine is a transdermal patch for
Parkinson's disease. A complex
formulation (not a simple tablet).
Fewer generic competitors. Higher
pricing power.
β EMA approval: December 2025 β
β EU commercial launch: Q1FY27
β USFDA ANDA filed: February 06, 2026 β
β EU market size: $222 million
β US market size: $112 million
Source: BSE filing Feb 06, 2026 +
https://t.co/NVpIoEpjeG Dec 2025
The same EU distribution partner
that built Nilotinib to βΉ290 Cr/year
is already in place for Rotigotine.
Revenue potential [Personal Estimate]:
β FY27E: βΉ50-80 Cr (EU year 1)
β FY28E: βΉ100-130 Cr (EU mature)
β FY29E: βΉ160-200 Cr (EU + US launch)
Current market price of this engine: βΉ0
π΅ VALVE 2: GLP-1 PEPTIDE PLATFORM
Status: π FACILITY BEING BUILT
The βΉ40 crore bet on a βΉ50,000 Cr
global window.
Every pharma company in the world
is hunting for reliable Semaglutide
and Liraglutide API supply before
the patent cliff hits in 2027-28.
Shilpa is building a 100+ kg peptide
facility. βΉ40 Cr of capex. H2FY27
completion. Liraglutide DMF already
filed (Q2FY26). Semaglutide validation
underway H2FY26.
Management's exact words, Feb 2026:
"Targeting the global GLP-1 patent
cliff in next 2-3 years. Facility will
produce 100kg+ of Semaglutide for
in-house and CDMO purposes."
Keshav Bhutada, Q3FY26 concall
βΉ40 Cr of capex chasing a single
CDMO contract worth βΉ200-500 Cr/year.
Revenue potential [Personal Estimate]:
β FY28E: βΉ80-150 Cr (CDMO batches)
β FY29E: βΉ200-400 Cr (scaled CDMO)
β FY30E: βΉ400-700 Cr (generics + CDMO)
Current market price of this engine: βΉ0
π΅ VALVE 3: ADC FACILITY + PIPELINE
Status: π Q4FY26 COMMISSIONING
India's first integrated ADC
manufacturing facility.
An ADC (Antibody Drug Conjugate) is
the most sophisticated oncology weapon
being developed globally right now.
An antibody acts as GPS. A chemotherapy
molecule is the payload. It kills only
cancer cells. It spares healthy tissue.
The ADC market is growing 25%+ CAGR.
Manufacturing capacity barely exists
outside 2-3 Western CDMOs.
Shilpa's facility covers payload
synthesis, linker chemistry, and
conjugation. End-to-end. No other
Indian company has this.
Key milestones:
β Facility: commissioning Q4FY26
β Own ADC (SBPL01): Phase I FY27
β Maptree: exclusive CDMO partner
Phase I human studies FY27
β Maptree Orphan Designation:
received for 2 indications β
Source: Q3FY26 concall transcript,
Alphastreet, Feb 08, 2026
What orphan designation means:
β 10 years US market exclusivity
β Priority regulatory review
β Premium pricing: 10-50x standard drugs
β Tax credits + fee waivers
One successful orphan ADC product
over its exclusivity period can be
worth more than Shilpa's current
entire market cap.
Revenue potential [Personal Estimate]:
β FY28E: βΉ30-80 Cr (CDMO trial)
β FY29E: βΉ100-200 Cr (commercial)
β FY30E: βΉ250-500 Cr (multiple programs)
Current market price of this engine: βΉ0
π΅ VALVE 4: NORΠ£ΠΠ‘Π (NODUCA)
Status: β
LAUNCHED. GROWING.
India's first and only therapy for
NAFLD (Non-Alcoholic Fatty Liver
Disease). Launched Q3FY26.
NAFLD affects 350 million Indians.
That is one in four people in this
country. Until Noduca, there was
literally no approved treatment for
any of them.
Management (Q3FY26 concall):
"Performance is exceeding expectations
and building a healthy order book."
First mover. First in class. 350 million
patients. Zero competition. Today.
β 3 large pharma distribution partners
+ Shilpa's own label in India
β RoW + US filings: FY27
β EU human studies: FY27
Revenue potential [Personal Estimate]:
β FY27E: βΉ50-80 Cr (India full year)
β FY28E: βΉ100-150 Cr (established)
β FY29E: βΉ150-250 Cr (global filings
convert to approvals)
EBITDA margin: 60%+ (own novel drug,
no API cost pressure, pricing power)
[Personal Estimate]
Current market price of this engine: βΉ0
π΅ VALVE 5: RECOMBINANT ALBUMIN
Status: π PHASE III. ORION DEAL SIGNED.
This is the most underappreciated
story in Indian pharma right now.
Human albumin is an ICU essential:
burns, liver disease, major surgery.
Current global supply: 100% plasma-
derived from donated blood. Limited.
Expensive. Supply-constrained.
Shilpa's sRbumin is made from
microbial cells. No donated blood.
Unlimited production. Safer.
What has already been accomplished:
β Phase I: completed August 2024 β
62 volunteers. Positive safety data.
First Indian company in history.
Source: PRNewswire, Aug 28, 2024
β Orion Corporation EU partnership:
signed May 2025 β
Exclusive EU distribution + marketing
+ sales. Major European pharma firm.
β Phase III India: ongoing (FY26)
β IMPD submission to EMA: Q4FY26 target
β India commercialization: FY28 guided
Source: Q3FY26 concall management
Global albumin market:
β 2026: $7.8 billion
β 2033: $13.1 billion
Source: CoherentMarketInsights 2026
Orion Corporation signing an exclusive
EU deal is the most powerful external
validation in this entire thesis. European
pharma companies do not sign distribution
exclusives with businesses that cannot
meet global quality standards. The
quality has been verified at the highest
level. The market has not noticed.
Revenue potential [Personal Estimate]:
β FY28E: βΉ30-80 Cr (India launch)
β FY29E: βΉ150-300 Cr (India + EU Orion)
β FY30E: βΉ400-700 Cr (full commercial)
Current market price of this engine: βΉ0
π΅ VALVE 6: AFLIBERCEPT BIOSIMILAR
Status: π PHASE III ONGOING
Aflibercept (brand: EYLEA) treats
wet AMD (age-related macular
degeneration). Standard of care.
Global market: approximately $5 billion.
Shilpa is in Phase III India for its
biosimilar version. EU Phase III
targeted for H1FY27. Out-licensed to
Alveolus Bio for global commercialization.
Eye biologics require double complexity:
ophthalmic formulation precision AND
biologic manufacturing capability.
Virtually no other Indian company
is at this stage.
Revenue potential [Personal Estimate]:
β FY28E: βΉ20-50 Cr (India launch)
β FY29E: βΉ80-150 Cr (India + global)
β FY30E: βΉ200-400 Cr (commercial scale)
Current market price of this engine: βΉ0
βββββββββββββββββββββββββββββ
Six engines. All priced at zero.
The market is pricing the steam
it can already see. The six sealed
valves are free. That is the
specific mispricing this post exists
to expose.
βββββββββββββββββββββββββββββ
π‘ SECTION 5: THE NEAR MISS
(WHERE SMART ANALYSTS GOT CLOSE)
βββββββββββββββββββββββββββββ
Most smart observers tracking Shilpa
in 2025 saw the Nilotinib EU scale-up
and concluded: "Formulations recovery
play. Buy on margin expansion."
They were almost exactly right.
They stopped one insight short.
The real insight is not that Nilotinib
EU is recovering Shilpa's margins.
The real insight is that Nilotinib EU
cash flow is FUNDING the construction
of six entirely different businesses
simultaneously. The recovery is the
foundation. The six engines are the
house being built on top of it.
The analysts who saw "margin recovery"
built a model that works if Nilotinib
holds and formulation mix improves.
That model gives a 20-30% upside.
The model that also prices the six
engines gives a 100-300% upside over
3-4 years. Same company. Same data.
Different second-order insight.
This is exactly the kind of gap that
creates asymmetric returns in markets.
The first conclusion is obvious. The
second requires connecting dots across
9 regulatory filings, 3 investor
presentations, and 5 concall transcripts.
βββββββββββββββββββββββββββββ
β οΈ SECTION 6: THE RISKS
(NON-NEGOTIABLE INTELLECTUAL HONESTY)
βββββββββββββββββββββββββββββ
A thesis without bear cases is not
a thesis. It is a promotional brochure.
Here are the three that matter most.
π΄ RISK 1: PROMOTER HOLDING DECLINE
Promoter holding: 44.23% (Sep 2025)
Promoter holding: 40.13% (Dec 2025)
Change: -4.1% in a single quarter.
Equivalent: ~βΉ300 Cr of shares sold.
Promoter pledge: 8.73% of holdings.
Official explanation: none provided.
This is the single most important
unresolved governance question in
this thesis.
Stock impact if selling continues:
20-30% correction on sentiment alone,
irrespective of business performance.
Lead indicator: BSE shareholding
pattern for March 2026 quarter,
due May 2026. If promoter falls
below 38% without explanation,
the investment thesis requires
immediate re-evaluation.
π΄ RISK 2: WORKING CAPITAL TRAP
FY25 Cash Conversion Cycle: 350 days.
Inventory Days: 309 (extremely high).
Receivable Days: 126 (rising trend).
Payable Days: 85 (fell from 156 FY24).
As revenue scales from βΉ1,500 Cr
toward βΉ2,500 Cr, each incremental
βΉ100 Cr of revenue could trap ~βΉ95 Cr
of additional working capital.
[Personal Estimate]
Strong PAT can coexist with a balance
sheet quietly deteriorating. The
P&L story looks great while cash
compounds in inventory and receivables.
Lead indicator: Inventory Days each
quarter on https://t.co/31hWWi2619. Below 280:
improving. Above 320: escalating risk.
π΄ RISK 3: BIOLOGICS CLINICAL FAILURE
βΉ822 Cr of Capital Work In Progress
on the FY25 balance sheet (March 2025).
This represents biologics facilities,
ADC infrastructure, and clinical assets.
Globally, clinical failure rates exceed
50% even in Phase III trials.
If Aflibercept or SBPL01 face adverse
clinical results, a βΉ150-300 Cr
write-off is possible. [Personal Estimate]
That would erase 2-3 years of PAT
in a single accounting year.
The biologics story is simultaneously
the highest upside and highest risk
element of this investment case.
Lead indicator: CTRI India for
Aflibercept Phase III interim results.
Any SEBI filing announcing clinical
program termination.
βββββββββββββββββββββββββββββ
π SECTION 7: THE SCENARIO MAP
[Personal Estimates Only. Not SEBI
Research. Not Investment Advice.]
βββββββββββββββββββββββββββββ
CMP: βΉ370 (NSE close, Apr 02, 2026)
FY26E (Mar 2027):
π Bull: EPS βΉ10.2 Γ P/E 45x = βΉ459 (+24%)
If: Q4FY26 PAT > βΉ55 Cr, ADC confirmed
π Base: EPS βΉ9.5 Γ P/E 40x = βΉ380 (+3%)
If: Steady execution, licensing βΉ150 Cr
π» Bear: EPS βΉ7.4 Γ P/E 30x = βΉ222 (-40%)
If: Licensing miss + API price pressure
FY27E (Mar 2028):
π Bull: EPS βΉ14.5 Γ P/E 52x = βΉ754 (+104%)
If: ADC CDMO deal + GLP-1 partnership
π Base: EPS βΉ13.5 Γ P/E 42x = βΉ567 (+53%)
If: 20%+ rev growth, Rotigotine launches,
API external ramp begins Q2FY27
π» Bear: EPS βΉ10.5 Γ P/E 28x = βΉ294 (-21%)
If: Nilotinib EU competition, delays
FY28E (Mar 2029):
π Bull: EPS βΉ19 Γ P/E 55x = βΉ1,045 (+182%)
If: ADC commercial + Albumin EU + GLP-1
π Base: EPS βΉ17.5 Γ P/E 45x = βΉ788 (+113%)
If: Biologics contribute, FCF positive
π» Bear: EPS βΉ13 Γ P/E 32x = βΉ416 (+12%)
If: Clinical delays + Nilotinib lost
FY29E (Mar 2030):
π Bull: EPS βΉ25 Γ P/E 58x = βΉ1,450 (+292%)
π Base: EPS βΉ22 Γ P/E 50x = βΉ1,100 (+197%)
π» Bear: EPS βΉ15 Γ P/E 35x = βΉ525 (+42%)
FY30E (Mar 2031):
π Bull: EPS βΉ31 Γ P/E 60x = βΉ1,860 (+403%)
π Base: EPS βΉ28 Γ P/E 52x = βΉ1,456 (+294%)
π» Bear: EPS βΉ18 Γ P/E 38x = βΉ684 (+85%)
Read the bear column carefully.
FY26 bear: -40%. FY27 bear: -21%.
FY28 bear: +12%. FY30 bear: +85%.
Time compresses your downside and
expands your upside simultaneously.
This is what a multi-year compounder
looks like before the market sees it.
EV/EBITDA cross-check [Personal Est]:
FY27E EBITDA βΉ535 Cr Γ 20x = βΉ10,700 Cr EV
Less Net Debt βΉ520 Cr = MCap βΉ10,180 Cr
TP = βΉ10,180 / 195.5 Cr shares = βΉ521
Consistent with P/E base. β
Peer context (Apr 2026):
β Divi's Labs P/E: ~60x (zero debt,
pristine USFDA record, 20%+ ROCE)
β Laurus Labs P/E: ~60x (CDMO-led
re-rating, ROCE 10-12%, D/E 0.62x)
β Shilpa at βΉ370 = P/E ~27x on FY27E
[Personal Estimate]
Shilpa deserves parity to Laurus when
CDMO contribution becomes visible in
reported numbers. That has not happened
yet. That is the gap.
βββββββββββββββββββββββββββββ
π SECTION 8: MANAGEMENT QUALITY
βββββββββββββββββββββββββββββ
Keshav Bhutada (ED and CEO) scored
4.5 / 5 on concall quality metrics
from Q3FY26 (Feb 06, 2026):
β Proactively disclosed licensing
income down 40%+ in 9MFY26. Did not
bury it. Named it. Explained it. β
β Gave specific numbers: βΉ150 Cr annual
licensing run-rate, βΉ40 Cr peptide
capex, Q1FY27 Rotigotine EU launch. β
β Explained the API diversion mechanism
clearly: internal API diversion to
captive formulations, external ramp
from Q2FY27. β
β Every prior quarter's guidance was
reiterated and confirmed. β
Capital allocation track record:
β Reduced Net Debt βΉ346 Cr in one year
(βΉ904 Cr FY24 to βΉ558 Cr FY25) β
β INM merger tax benefit captured via
NCLT approval Q1FY26. Smart financial
engineering that saved real tax rupees. β
β Biologics CWIP βΉ822 Cr (Mar 2025):
high but represents real future assets.
GLP-1 capex βΉ40 Cr is disciplined
given the market opportunity size. β
The one unresolved concern:
β Promoter: 40.13% (Dec 2025), down
4.1% in one quarter. Pledge: 8.73%.
No public explanation provided. β οΈ
Operational quality: high.
Governance question: one open item.
Watch May 2026 shareholding filing.
βββββββββββββββββββββββββββββ
π
SECTION 9: CATALYST CALENDAR
(Next 18 Months, High to Low Impact)
βββββββββββββββββββββββββββββ
π΄ [CRITICAL] May 2026:
BSE Q4FY26 results + concall.
β ADC Q4FY26 commissioning: confirmed
or delayed?
β Full year FY26 PAT vs βΉ185 Cr base
[Personal Estimate]
β Management FY27 revenue guidance
π΄ [CRITICAL] May 2026:
BSE shareholding pattern (Mar 2026).
β Promoter direction: the most
important governance data point
in the next 6 months
π‘ [HIGH] Q1FY27 (Apr-Jun 2026):
Rotigotine EU first commercial revenue.
β EU Formulations above βΉ90 Cr in
Q1FY27 results = Rotigotine launched
β The first sealed valve opening in
reported numbers
π‘ [HIGH] H1 FY27 (by Sep 2026):
GLP-1 CDMO partnership announcement.
β Any signed CDMO deal for Semaglutide
or Liraglutide = immediate re-rating
(market cannot ignore $50B+ TAM)
π‘ [MED] Q4FY26 (by Jun 2026):
Albumin IMPD submission to EMA.
β Confirms the Orion EU partnership
is executing on schedule
β European commercial pathway opening
βββββββββββββββββββββββββββββ
π SECTION 10: THE VERDICT
βββββββββββββββββββββββββββββ
You now know three things most
market participants have missed:
1. THE MISPRICING:
The market's mental model of Shilpa
is built on FY23 data. The company
earning 2x its previous year's
profit in just 9 months, at 28%
EBITDA margins, with 17% adjusted
ROCE, is not the company in that
mental model. The narrative has not
caught up to the numbers.
2. THE DATA THAT PROVES IT:
Nine months. βΉ146 Cr adjusted PAT.
A signed EU albumin deal with Orion.
An ADC facility commissioning this
quarter. A GLP-1 plant being built
for βΉ40 Cr chasing a $50B+ market.
India's first NAFLD drug already
exceeding sales expectations.
Six engines priced at zero.
3. WHAT IT MEANS FOR THE NEXT
12-36 MONTHS:
FY26 base case upside is modest (+3%).
This is not a FY26 trade.
FY27 base case is +53%, with the first
sealed valve (Rotigotine EU) opening
visibly in reported quarterly numbers.
FY28 base case is +113%, if biologics
begin contributing even partially.
The bear case in FY30 still gives
you +85% from today's price.
Time is the most powerful risk manager
in this thesis.
The pressure cooker has been building
heat for 4 years. The first valve
opened in December 2025. Five remain
sealed. All five are priced at zero.
I have spent considerable time across
pharma balance sheets looking for
exactly this: a business where verified
execution is funding the construction
of optionalities the market cannot yet
see on any income statement. Shilpa at
βΉ370 is one of the clearest examples
of this structure I have encountered
in Indian small-cap pharma. The
combination of compounding core
business + free biologics optionality
+ disciplined management communication
is genuinely rare. That is not hype.
That is a specific, falsifiable claim
supported by the data in this thread.
The market is pricing the steam it
can already see escaping. Five valves
remain sealed. Five opportunities
are currently free.
Here is the question worth debating
in the comments: At exactly what
quarterly revenue milestone from
Rotigotine EU, GLP-1, or ADC does
the market's re-rating from API-
multiple to CDMO-biologics-multiple
actually trigger? βΉ50 Cr/quarter?
βΉ100 Cr/quarter? What is the number
that breaks the old narrative
irreversibly?
If you are reading a 360Β° pharma
thesis at this level of granularity,
you already know something most
market participants will only
understand after the re-rating
has happened. That window is now.
βββββββββββββββββββββββββββββ
β οΈ NOT SEBI registered research.
β οΈ NOT investment advice.
β οΈ ALL projections = personal estimates.
β οΈ Do your own research. Always.
#ShilpaMedicare #SHILPAMED
Follow for deep-dive equity research π
βββββββββββββββββββββββββββββ](https://pbs.twimg.com/media/HE7IDGDacAAluxD.jpg)
Last Seen Users on Sotwe
aleynaπ°π·
Seen from Turkey
ΰ΄€ΰ΅ΰ΄Άΰ΅ΰ΄Άΰ΄ΰ΅ΰ΄ΰ΄Ύΰ΄°ΰ΅» ΰ΄ͺΰ΄―ΰ΅ΰ΄―ΰ΅»
Seen from India
λ΄μ·¨ν₯μΌλβ€οΈ
Seen from Korea
UK Pleasure Boys 
Seen from United Kingdom
TWθεΈζ©η΄ δΊΊε€ζ΅εΊε°π
Seen from Malaysia
FOLLOW π
Seen from Pakistan
Ψ³Ω
Ψ³ΩΨ±Ω π¦
Seen from Jordan
pengembala
Seen from Indonesia
Ψ¬Ψ§ΩΫΨ― Ψ§Ω Ψ΄Ψ§Ψ²ΫΩ Ϊ©ΩΎΩ Ϊ©ΩΩΨ§Ψͺ ΩΩ
Seen from Singapore
khusus bokep jepang +18
Seen from Malaysia
Trends for you
Most Popular Users
Elon Musk
@elonmusk
241.2M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.9M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.3M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.5M followers
KATY PERRY
@katyperry
89.1M followers
Taylor Swift
@taylorswift13
83M followers
Lady Gaga
@ladygaga
74.5M followers
Virat Kohli
@imvkohli
72M followers
Kim Kardashian
@kimkardashian
70.5M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
64.9M followers
Bill Gates
@billgates
64.6M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
62.1M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers